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Resistance to amikacin (AMK) and kanamycin (KAN) in clinicalMycobacterium tuberculosis strains is largely determined by
specific mutations in the rrs gene and eis gene promoter. We developed a rapid, multiplexed sloppy molecular beacon (SMB) as-
say to identify these mutations and then evaluated assay performance on 603 clinicalM. tuberculosisDNA samples collected in
South Korea. Assay performance was compared to gold-standard phenotypic drug susceptibility tests, including Lowenstein-
Jensen (LJ) absolute concentration, mycobacterial growth indicator tubes (MGIT), and TREK Sensititre MycoTBMIC plate
(MycoTB) methods. Target amplicons were also tested for mutations by Sanger sequencing. The SMB assay correctly detected
115/116 mutant andmixed sequences and 487/487 wild-type sequences (sensitivity and specificity of 99.1 and 100%, respec-
tively). Using the LJ method as the reference, sensitivity and specificity for AMK resistance were 92.2% and 100%, respectively,
and sensitivity and specificity for KAN resistance were 87.7% and 95.6%, respectively. Mutations in the rrs gene were unequivo-
cally associated with high-level cross-resistance to AMK and KAN in all three conventional drug susceptibility testing methods.
However, eis promoter mutations were associated with KAN resistance using theMGIT orMycoTBmethods but not the LJ
method. No testing method associated eis promoter mutations with AMK resistance. Among the discordant samples with AMK
and/or KAN resistance but wild-type sequence at the target genes, we discovered four newmutations in thewhiB7 5= untrans-
lated region (UTR) in 6/22 samples. All six samples were resistant only to KAN, suggesting the possible role of thesewhiB7 5=
UTRmutations in KAN resistance.
Tuberculosis (TB) was declared a global public emergencynearly 20 years ago (1). Although the rate of new cases of TB
has been decreasing worldwide, the millennium developmental
goal target of a 50% disease reduction by 2015 is unlikely to be
achieved (1). An increase in the incidence of multidrug-resistant
(MDR) and extensively drug resistant (XDR)TB is a serious threat
to these reduction goals (1). Patients with drug-resistant TB are
best identified as rapidly as possible so that appropriate infection
control and treatments can be quickly initiated (2).
Conventional phenotypic methods can take weeks to months
to fully define the drug resistance pattern ofMycobacterium tuber-
culosis isolates due to the very slow growth of this bacterium (3–5).
Molecular tests offer the promise of more rapid drug resistance
detection. A number of tests are available to detect resistance to
many of the first-line anti-TB drugs (6–8). However, there are
fewer rapid tests available to test for resistance to the injectable
second-line drugs amikacin (AMK), kanamycin (KAN), and
capreomycin (CAP). DNA sequencing studies suggest that most
cases of resistance to injectable drugs can be identified by detect-
ing mutations in positions 1401, 1402, and 1484 in the M. tuber-
culosis 16S rRNA (rrs) gene and between nucleotides10 to37
of the M. tuberculosis eis gene promoter region (9–13) although
sensitivity and specificity for detecting resistance have varied in
different studies. The reverse line blot hybridization assay, Geno-
Type MTBDRsl test (Hain Lifescience, Germany), which targets
mutations in the rrs gene, is currently undergoing validation in
trials, as reported in several studies (14). However, the open hy-
bridization system format of line probe assays, which require rig-
orous physical separation of different work areas to prevent am-
plicon cross-contamination (15, 16), and the absence of probes
targeting the eis promoter mutations are likely to limit the sensi-
tivity and specificity of the assay (17, 18). Several other molecular
techniques which detect resistance to the injectable drugs have
been described recently. These include in-house reverse line blot
Received 18 July 2014 Returned for modification 22 August 2014
Accepted 13 October 2014
Accepted manuscript posted online 22 October 2014
Citation Chakravorty S, Lee JS, Cho EJ, Roh SS, Smith LE, Lee J, Kim CT, Via LE, Cho
S-N, Barry CE, III, Alland D. 2015. Genotypic susceptibility testing of Mycobacterium
tuberculosis isolates for amikacin and kanamycin resistance by use of a rapid
sloppy molecular beacon-based assay identifies more cases of low-level drug
resistance than phenotypic Lowenstein-Jensen testing. J Clin Microbiol 53:43–51.
doi:10.1128/JCM.02059-14.
Editor: G. A. Land
Address correspondence to Soumitesh Chakravorty, chakraso@njms.rutgers.edu.
S.C. and J.S.L. contributed equally to this study.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.02059-14
January 2015 Volume 53 Number 1 jcm.asm.org 43Journal of Clinical Microbiology
hybridization assays, multiplex allele-specific PCR, mass spec-
trometry of PCR products using iPLEX Gold assay (MassArray
System; Sequenom, Inc., San Diego, CA, USA), oligonucleotide
microarray, and melting curves using dually labeled probes (19–
24). However, most of these techniques require open handling of
PCR amplicons or have not been systematically validated in clin-
ical settings.
We have recently described two separate sloppymolecular bea-
con (SMB) assays that rapidly and reliably identify the M. tuber-
culosis mutations that are largely responsible for rifampin and
fluoroquinolone (FQ) resistance (25, 26). These assays have the
advantage of being in real-time PCR format so that they are easy to
use and not subject to amplicon cross-contamination. Moreover,
mutation detection has been shown to be robust and amenable to
high-throughput testing. Here, we present a further extension of
our SMB TB drug resistance detection assay system, adding assays
that enable detection of resistance to AMK and KAN. We also
explore the causes of discordance between our assay and pheno-
typic susceptibility testingmethods.Our results show that some of
the most commonly used phenotypic methods canmissM. tuber-
culosis isolates with resistance-conferring mutations if these mu-
tations only moderately increase MICs of KAN. Novel mutations
in whiB7 that are associated with low-level KAN resistance were
also discovered.
MATERIALS AND METHODS
DNA samples. M. tuberculosis test samples consisted of DNA isolated
from 603 sequential M. tuberculosis isolates cultured from 503 patients
enrolled in a natural history study of MDR tuberculosis (registered at
ClinicalTrials.gov under no. NCT00341601) in the National Masan Hos-
pital in Changwon, Republic of Korea. Two cohorts were tested. Cohort A
consisted of treatment-naive newly suspected TB cases (158 samples), and
cohort B consisted of retreatment TB cases (445 samples). Fresh sputum
samples were collected from each patient at the onset of treatment and
cultured forM. tuberculosis. In a subset of patients, repeat sputum samples
were collected at the 1st, 4th, and 6th month of treatment and also cul-
tured for M. tuberculosis. Nontuberculosis mycobacteria (NTM) and
Gram-positive and Gram-negative bacteria test samples were taken from
the New JerseyMedical School (NJMS) DNA repository as described pre-
viously (26).
Phenotypic drug susceptibility testing. Phenotypic drug susceptibil-
ity testing was performed on all 603 isolates by the absolute concentration
method on LJ medium to determine the susceptibility to AMK and KAN
using a critical concentration of 40 g/ml (the standard concentration
used during 2012 when the isolates were tested) for both the antibiotics
(27) at the International Tuberculosis Research Center (ITRC), South
Korea. MICs of AMK and KAN for 173/603 samples were also evaluated
using TREK Sensititre MycoTB MIC plates (MycoTB; TREK Diagnostic
Systems, Cleveland, OH, USA) as described previously (28). For 560/603
samples, resistance to KAN was also evaluated using a mycobacterial
growth indicator tube (MGIT) system (BectonDickinson, Franklin Lakes,
NJ, USA) at a critical concentration of 2.5 g/ml. For the samples with
phenotypic susceptibility test results that were discordant with Sanger
sequencing results of the target genes, the phenotypic susceptibility tests
were repeated to confirm the initial findings. In cases whereMGIT and LJ
susceptibility test results showed discordance, both the assays were re-
peated to confirm or rectify the initial findings.
DNA preparation and sequencing. DNA for both SMB assay testing
and Sanger sequencingwas prepared from cultured isolates by boiling one
loopful of culture in 200 l of InstageneMatrix resin (Bio-Rad Laborato-
ries, Hercules, CA,USA) in the presence of 0.1%TritonX-100 for 10 to 15
min. The supernatant was recovered after centrifugation and quantified
using a NanoDropmicrovolume spectrophotometer (Thermo Fisher Sci-
entific, Waltham, MA, USA). For Sanger sequencing, two different frag-
ments of the rrs gene (nucleotides 420 to 980 and 1293 to 1537) and a part
of the upstream eis coding region plus the entire eis promoter were am-
plified using 0.5Meach forward and reverse primer, 1PCRbuffer, 250
mM deoxynucleoside triphosphates (dNTPs), 2.5 mM MgCl2, and 0.03
U/l of AmpliTaq Gold DNA polymerase enzyme (Applied Biosystems,
Foster City, CA, USA) according to the following parameters: initial de-
naturation at 95°C for 10 min, followed by 40 cycles of 95°C for 10s,
58-60°C for 30s and 72°C for 10 to 30s depending on the amplicon size.
The eis promoter region and the rrs gene fragments were amplified as
described previously (13, 29). For a subset of samples, a 538-bp fragment
from thewhiB7 gene including 412 bpof the 5=untranslated region (UTR)
and 126 bp from the open reading frame (ORF) was amplified and se-
quenced using primers whiB7F (5=-AAACGCGCAGGTCAGAAAAT-3=)
and whiB7R (5=-CAGTGTCTTGGCTACCTCGA-3=). Additionally, a
275-bp fragment from the whiB7 gene, which included almost the entire
whiB7 ORF, was also amplified using the primers whiB7-ingene-F (5=-G
TCGGTACTGACAGTCCCC-3=) and whiB7-ingene-R (5=-ATGCAACA
GCATCCTTGCG-3=). The PCR products were subjected to bidirectional
sequencing using gene-specific forward and reverse primers in a 3130XL
genetic analyzer (Applied Bio-systems, Foster City, CA, USA) using a
BigDye Terminator, version 3.1, cycle sequencing kit (Applied Biosys-
tems) according to the manufacturer’s instructions.
Assay molecular beacons and primers. The SMB assays targeted M.
tuberculosis mutations in codons 1401 and 1402 of the rrs gene and mu-
tations along the promoter region of the eis gene. A 113-bp fragment
(nucleotides 1335 to 1451) was amplified from the rrs gene using the
primers AMG-F (5=-GCTAGTAATCGCAGATCAGCAACGCTGC-3=)
and AMG-R (5=-CCTCCCGAGGGTTAGGCCACT-3=), and a 98-bp
fragment encompassing the promoter region and the initial five codons of
the eis gene (nucleotides81 to 17) was amplified using the primers eis-F
(5=-CACAGGGTCACAGTCACAGAATC-3=) and eis-R (5=-GCATCGC
GTGATCCTTTGCCAGAC-3=). The rrs primers were designed to be spe-
cific to Mycobacterium genus, and the eis primers were designed to be
specific to the M. tuberculosis complex. One SMB probe, rrs-1400 (5=-6-
carboxyfluorescein-CACGACCGCCCGTCACGTCATGAAAGTCGGT
CGTG--BHQ1-3=), and two SMB probes, eis-1 (5=-Cy5-CAGGCGGTCG
TAATATTCACGTGCACCTGGCCGCCGCCTG-BHQ2-3=) and eis-2
(5=-TexasRed-CTCGCGGCATATGCCACAGTCGGATTCTCTGACGC
GAG-BHQ2-3=) (where underlined sequences represent the stem portion
of the SMB and BHQ represents black hole quencher), were targeted
against the rrs gene and the eis promoter region, respectively. The rrs
probe was designed to be complementary to the antisense strand, and the
eis probes were designed to be complementary to the sense strand. The
SMBs were designed using the in silico DNA folding program at http:
//mfold.rna.albany.edu/?q_mfold/dna-folding-form, and the probe-tar-
get hybrid folding program at http://mfold.rna.albany.edu/?q_DINAMelt
/Two-state-melting was used to predict the possible probe-target hybrid
structures and melting temperatures (Tms). The probes were designed to
generate a maximum Tm difference between wild-type and mutant se-
quences in their respective target regions to enable unambiguous muta-
tion identification. Primers were obtained from Sigma-Aldrich (St. Louis,
MO, USA), and SMB probes were from Biosearch Technologies (Novato,
CA, USA).
Assay procedure. All the samples were independently coded and ran-
domly distributed to ensure that assay validation was performed in a
blinded manner. The assay was tested at both ITRC in Masan, South
Korea, and the New Jersey Medical School (NJMS), Rutgers, Newark, NJ.
Once testing of the entire 603 sample set was completed, the samples were
decoded, and the PCR results were compared to the corresponding se-
quencing and phenotypic drug susceptibility testing results. The results
obtained at each site were also compared. Assay results were not reported
to the treating physicians and were not used to guide any treatment deci-
sions. PCR was performed in 384-well plates using a Roche LightCycler
480 II real-time PCR system (Roche Diagnostics Co., Indianapolis, IN,
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USA) in 20-l reaction volumes containing 100 nM forward primer and 1
M reverse primer for the rrs gene and 1 M forward primer and 50 nM
reverse primer for the eis promoter region, 1 ng/l of rrs-1400 and eis-1
probes and 0.8 ng/l of eis-2 probe, 4 mMMgCl2, 250 mM deoxynucleo-
side triphosphates (dNTPs), 1 PCR buffer, 8% glycerol, 0.06 U/l of
Platinum TfiExo() DNA polymerase (Life Technologies, Grand Island,
NY, USA), and 2 to 5 ng of sample DNAor an equivalent volume of water.
PCRwas carried out with the following steps: activation of the enzyme for
2 min at 95°C, followed by 50 cycles of denaturation at 95°C for 10s and
combined annealing and extension at 67°C for 30s. Following PCR cy-
cling, post-PCR Tm analysis was performed by denaturation at 95°C for 2
min, followed by cooling down to 45°C and then gradual heating to 85°C,
with continuousmonitoring of fluorescence during the process at a rate of
1 datumacquisition per degree centigrade.Tm valueswere identified at the
end of the reaction using the Tm calling software (LightCycler 480 soft-
ware). However, each Tm value was also verified by a trained observer
before the final identification of the Tm value was made. Samples showing
distinct double peaks for any probes corresponding to wild-type andmu-
tant Tms were considered to be indicative of heteroresistance. A no-tem-
plate control using sterile water instead of DNA as the template was used
as the DNA-negative control, and a DNA-positive control using 1 ng of
genomic DNA from M. tuberculosis H37Rv as the template was also in-
cluded in each assay plate.
Human subject approvals. This study was approved by the National
Masan Hospital, NIAID, and Rutgers (formerly University of Medicine
and Dentistry of New Jersey [UMDNJ]) institutional review boards
(IRBs), and all subjects gave written informed consent (Rutgers IRB pro-
tocol number 0120090104).
RESULTS
Identification of Tm values associated with wild-type and mu-
tant sequences.Our SMB-based assay detected resistance toAMK
and KAN by looking for mutations in the M. tuberculosis rrs gene
and eis promoter that have known associations with resistance.
The assay consisted of a PCR step followed by a Tm analysis in the
presence of SMB probes complementary to portions of the rrs and
eis target amplicons. We first evaluated the capability of the assay
to identify the target mutations on artificial oligonucleotides and
sequencedDNA templates from selectedwild-type andmutantM.
tuberculosis strains (data not shown). Wild-type sequences were
identified by the presence of Tm values within 1°C of the known
mean values for wild-type targets. Mutant sequences were identi-
fied by a shift in Tm values of at least 5 standard deviations away
from the mean wild-type Tm values. The ability of the assay to
detect the most prevalent mutations associated with AMK and
KAN resistance was then evaluated on the clinical DNA samples.
Tests were performed on a panel of 603 clinical samples, consist-
ing of 487 samples with wild-type sequences and 116 samples with
mutations in the assay targets. Five of these samples had mixtures
of both wild-type and mutant DNA detected on Sanger sequenc-
ing. The SMB assay correctly identified 115/116 (99%) mutant or
mixed (heterogeneous samples containing bothmutant and wild-
type DNA) samples asmutant ormixed and 487/487 (100%) pure
wild-type samples as wild type. A single mixed sample (as indi-
cated by Sanger sequencing) was identified as a wild-type sample
by our assay. The Tm values produced by each SMB probe in the
setting of wild-type or mutant targets were highly reproducible.
For wild-type targets, probes rrs-1400, eis-1, and eis-2 showed
meanTm values of 70.1 0.15°C, 63.9 0.19°C, and 69 0.23°C,
respectively (Table 1). For mutant Tm targets, A1401G and
C1402T, themutations resulted in 3.9°C ( 0.17°C) and 5.6°C (
0.21°C) decreases, respectively, in Tm values in probe rrs-1400
(Table 1). Similarly, the eis-1 and the eis-2 probes robustly de-
tected a range of mutations in the eis promoter region as mutant
by developing a decrease in Tm values of 4.3°C to 6.5°C compared
to the expected wild-type Tm values (Table 1). The PCR assays
performed in the two different laboratories at Rutgers and ITRC
TABLE 1 Melting temperature (Tm) values of the rrs and eis probes tested against clinical DNA with wild-type and mutant sequences
Gene(s) and/or
sequence type
Mean Tm (°C) Tm SD (°C) Tm (°C)
a
No. of isolates
detected/total
no. of isolates
with the
mutationrrs-1400 eis-1 eis-2 rrs-1400 eis-1 eis-2 rrs-1400 eis-1 eis-2
NMb 70.10 63.90 69.00 0.15 0.19 0.23 487/487
rrs gene
A1401G 66.20 63.90 69.10 0.10 0.20 0.20 3.90 0.00 0.10 75/75
A1401G NM 66.20, 70.10c 64.00 69.10 0.18 0.10 0.10 3.90 0.10 0.10 3/4
C1402T NM 64.50, 70.10c 64.10 69.20 0.00 0.00 0.00 5.60 0.20 0.20 1/1
eis promoter
C(8) deletion 70.10 64.10 63.10 0.00 0.00 0.00 0.00 0.20 5.90 1/1
G(10)A 70.20 63.80 64.70 0.10 0.20 0.20 0.10 0.10 4.30 14/14
G(10)A NM 70.20 63.80 64.80, 69.10c 0.10 0.20 0.20 0.10 0.10 4.20 1/1
C(12)T 70.15 64.04 62.92 0.08 0.22 0.03 0.05 0.13 6.08 2/2
C(14)T 70.10 64.00 62.60 0.10 0.20 0.20 0.00 0.10 6.40 10/10
G(37)T 70.20 58.80 69.10 0.10 0.10 0.20 0.10 5.10 0.10 4/4
rrs gene eis promoter
rrs A1401G eis
C(14)T
66.30 64.10 62.50 0.12 0.14 0.17 3.80 0.20 6.50 4/4
a Tm, difference between the value of the mutant sequence and the wild-type sequence for each probe. The shaded areas represent the Tm indicating the mutations.
b NM, no mutation (wild type). Heterogeneous samples contained both mutant and wild-type ( NM) sequence.
c Samples with mixed DNA. The two different Tms correspond to mutant and wild-type Tms, respectively.
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were in complete agreement for all the samples detected as wild
type and mutant as well as mixtures.
Our assay results enabled us to clearly segregate the 603 sam-
ples into wild-type and mutant Tm cluster types based on their
individual three-point Tm patterns (Fig. 1). The assay correctly
identified mutations in all 75 samples that contained only the
A1401Gmutation (Table 1 and Fig. 2A). Three of the four samples
containing mixtures of A1401G and wild-type sequence were also
detected as mixed wild type/mutant based on the presence of a
double Tm peak. A single sample that contained a mixture of the
C1402T mutation and wild-type DNA was also identified by the
presence of double Tm peaks from the sample with a mutant Tm
specific for the C1402T mutation (Table 1 and Fig. 2A). The 32
samples with eis promoter region mutations included five differ-
ent polymorphisms (at positions8,10,12,14, and37).
All of these mutations were successfully detected by one of the eis
SMBs (Table 1 and Fig. 2B and C). Four samples that had muta-
tions in both the rrs gene and the eis promoter region were also
correctly detected as double mutants (Table 1). Sequencing of the
rrs gene did not identify any samples with a codon 1484mutation,
regardless of its drug susceptibility pattern.
Identification of amikacin resistance. We next evaluated the
performance of our molecular assay relative to phenotypic drug
susceptibly test results. The apparent performance of a genotypic
drug susceptibility test can vary depending on the mutations se-
lected for inclusion in the test and the phenotypic assay that is used
as a gold standard (4, 30, 31). Considering the LJ-based drug sus-
ceptibility testing method as the gold standard (performed for all
of the 603 study samples), the SMB assay classified 82/90 of the
AMK-resistant samples as resistant using the rrs Tm characteristic
of the A1401G mutation (sensitivity of 91.1%; 95% confidence
interval [CI], 82.8% to 96.8%). Using the wild-type Tm, the assay
classified 512/513 of the AMK-susceptible samples as susceptible.
A single isolate among the 513AMK-susceptible isolates was iden-
tified as a mixture of wild-type and C1402T mutant DNA by our
SMB assay due to the presence of a clear double peak generated by
the rrs SMB probe, corresponding to the wild-type Tm and a spe-
cific C1402T mutant Tm (Fig. 2A). This was also confirmed by
Sanger sequencing. Since previous studies have shown that the
C1402T mutation does not code for AMK resistance (32), the
specificTm corresponding to the C1402Tmutation can be consid-
ered an indicator of AMK susceptibility. This consideration re-
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FIG 1 Detection of AMK and/or KAN resistance in 603 clinical DNA samples
using an SMB probe-generated three-point Tm profile. Each of the three assay
SMBs were tested against allM. tuberculosisDNA samples in a multiplex PCR.
The results for each sample are shown as a three-point Tm plot on the x axis,
with the Tm value of each SMB indicated on the y axis. Isolates are sorted from
left to right as phenotypically susceptible and then as resistant. Distinct Tm
shifts from at least one of the three probes can be seen in each resistant isolate.
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FIG 2 First-derivative melt peak profiles of each SMB probe. The melt peak profiles of wild-type, mutant, and mixed DNA samples are shown for the rrs-1400
SMB probe (A), the eis-1 SMB probe (B), and the eis-2 SMB probe (C). Each melt curve represents an individual strain.
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sulted in our assay correctly detecting all 513/513 AMK-suscepti-
ble samples, resulting in a specificity of 100% (95% CI, 99 to
100%). Including Tm values characteristic for mutations in the eis
promoter region in the analysis did not increase the sensitivity for
detecting AMK resistance but decreased the specificity from 100%
to 93.8% (95% CI, 91.2 to 95.6%). These results are consistent
with previous reports which suggest that the eis promoter muta-
tions are not associated with AMK resistance as defined by the LJ
drug susceptibility testing (9, 33).
Identification of kanamycin resistance. The performance of
our assay to detect KAN resistance was also evaluated using LJ-
based drug susceptibly testing as the gold standard for all 603
samples. Using Tm values generated by our rrs SMB typical for
either the A1401G or the C1402T mutation to define resistance,
the assay detected 82/106 samples as KAN resistant (sensitivity,
77.4%; 95% CI 68.0 to 84.7%). Conversely, using an rrs SMB Tm
characteristic for a wild-type target to define susceptibility, the
assay identified 496/497 KAN-susceptible samples as susceptible
(Table 2) (specificity, 99.8%; 95% CI, 98.7 to 100%). Adding Tm
values of the two eis SMBs characteristic for mutations in the eis
promoter region to our definition of resistance increased the sen-
sitivity of the assay for detecting KAN resistance from 77.4% to
87.7% (95%CI, 79.5 to 93%) as 11 additional KAN-resistant sam-
ples were classified as resistant. However, specificity decreased
from 99.8% to 95.6% (95%CI, 93.3 to 97.1%) as 21 KAN-suscep-
tible samples with eis promoter mutations were now “falsely” de-
tected as KAN resistant (Table 2).
We then performed a similar analysis using MGIT-based drug
susceptibility test results as the gold standard for the 560 of the
samples for which a MGIT result was available. This subset in-
cluded all the samples harboring only eis promoter mutations.
Comparison of our assay results to theMGIT-based gold standard
helped to clarify the eismutantswith discordantKAN resistance in
LJ medium. Using MGIT as the gold standard and only the rrs
SMBTm values characteristic for the A1401GorC1402Tmutation
to define KAN resistance, only 63/113 KAN-resistant samples
were identified as resistant by the SMB assay (sensitivity, 55.8%;
95% CI, 46.1 to 65%). Conversely, using the rrs SMB Tm charac-
teristic for the wild-type target to define susceptibility, the assay
identified 445/447 samples as KAN susceptible (specificity, 99.8%;
95% CI, 98.5 to 100%) (Table 2). Unlike the case with LJ-based
susceptibility testing, including the Tm values characteristic for eis
promotermutations in this case increased sensitivity for resistance
testing from 55.8% to 82.3%, with the specificity of the assay for
KAN resistance still remaining very high at 99.5% (95%CI, 98.2 to
100%). Thus, based on an MGIT-based susceptibility test, the eis
assay allowed the detection of 29 additional KAN-resistant sam-
ples without affecting specificity (Table 2).
Relationship between mutations detected by the assay and
MIC. The discordance between resistance as defined by our assay
and resistance as defined by our two phenotypic susceptibility test
methods principally involved isolates with eis promoter muta-
tions. Previous studies have shown that the eis promoter muta-
tions give rise to relatively low levels of KAN resistance, while rrs
gene mutations result in high-level resistance to AMK, KAN, and
CAP (9, 10, 12, 33). An additional finding in our results was the
discordance that we observed between LJ- and MGIT-based sus-
ceptibility test results. We performed MIC testing to more care-
fully explore the relationship between rrs and eis promoter muta-
tions and their differential susceptibility patterns in the LJ and the
MGIT systems. Samples that were either susceptible to both AMK
andKAN (andwild type at both the target regions) or chosen to be
representative of the most common mutation types in the two
target genes [the A1401G mutation in rrs and the eis promoter
regionmutationsG(10)A, C(14)T, andG(37)T]were tested
by the MycoTB method to determine the MICs. Additional iso-
lates known to be wild type in both of our assay targets were also
tested as controls.We observed that the AMKMICs of the isolates
that had only eis promoter mutations (without rrs mutations)
ranged between 0.25 g/ml and 2 g/ml, with the majority of
samples showingMICs of 0.5g/ml to 1g/ml (Fig. 3). Only one
eis promoter mutant had an AMK MIC of 4 g/ml. Control iso-
lates with no eis promoter or rrs mutations had AMK MICs be-
tween 0.25 g/ml and 0.5 g/ml. Thus, the AMK MICs of the
isolates with either wild-type or mutant eis promoter sequences
overlapped substantially. In contrast, the KAN MICs for most of
the same eis promoter mutants ranged from 5g/ml to 20g/ml,
with one isolate showing anMIC of 40g/ml (Fig. 3). Only one eis
promoter mutant had a low KAN MIC (2.5 g/ml). The isolates
with wild-type eis promoter sequences showed KAN MICs be-
tween 0.6 g/ml to 2.5 g/ml, which is 2- to 30-fold less than the
meanMIC of the eis promoter mutants (Fig. 3). Thus, in contrast
to the situationwithAMK, theKANMICs of thewild-type isolates
overlapped very little with the KAN MICs of the eis promoter
mutants. These results strongly suggest that eis promoter mutants
should be considered to have low- to moderate-level KAN resis-
TABLE 2 Susceptibility of the clinical strains to AMK and KAN by the LJ and MGIT methods and their relation to the mutations present in the rrs
gene and the eis promoter region
Test method and drug
susceptibilitya
No. of isolates detected by genotype
Total no. of
isolatesrrs A1401G rrs C1402T
eis promoter
mutation
Wild-type rrs gene and
eis promoter
LJ
AMK resistant 82 0 1 7 90
AMK susceptible 0 1 31 481 513
KAN resistant 82 0 11 13 106
KAN susceptible 0 1 21 475 497
MGIT
KAN resistant 63 0 30 20 113
KAN susceptible 1 0 1 445 447
a LJ and MGIT susceptibility as determined by the LJ proportions and the MGIT methods respectively.
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tance even if resistance is not detected on LJ-based or evenMGIT-
based susceptibility tests.
Assay specificity against bacteria other thanM. tuberculosis.
The analytical specificity of the assay was tested against a panel of
18 species of nontuberculousmycobacteria (NTM)obtained from
the ATCC repository (Manassas, VA, USA), 121 clinical NTM
strains representing 26 species, and 18 species of Gram-positive
andGram-negative bacteria. The rrs region targeted in our assay is
highly conserved among different NTM species. Thus, the rrs as-
say generated a Tm of 70°C (which is identical to the Tm generated
in the presence of wild-typeM. tuberculosisDNA) for all the NTM
strains tested, as expected based on sequence homology forMyco-
bacterium xenopi, which did not generate any Tm. The NTM spe-
cies which generateTm values identical to aminoglycoside-suscep-
tible M. tuberculosis strains would not be expected to cause a false
resistance test result. When M. tuberculosis DNA from rrs mutant
AMK- and KAN-resistant strains was mixed with a 10- to 20-fold
excess of NTM DNA, a distinct double Tm peak was produced by
the assay, corresponding to a mutant Tm value from theM. tuber-
culosis target and a wild-type Tm value from the NTM sequence
(data not shown), indicating that resistance-associated rrs muta-
tions can be detected in M. tuberculosis by our assay even in the
presence of a large background of NTM DNA. No visible melt
curve was generated by the eis probes in the presence of any NTM
species tested even when 107 genome equivalents of DNA was
added to the PCR assay. None of the Gram-positive or Gram-
negative bacteria produced Tm values to any of the rrs or eis SMBs;
thus, they did not cause any false resistance calls to bemade by the
assay.
Additional genetic causes of AMK and KAN resistance. Our
study included 22 samples that were resistant to AMK and/or
KAN but had wild-type rrs gene and eis promoter sequences. Re-
cent investigations have suggested that mutations in the 5= un-
translated region (UTR) of the whiB7 gene may cause aminogly-
coside resistance in M. tuberculosis (34). To determine whether
whiB7mutations could be responsible for some of our phenotyp-
ically resistant but assay-susceptible isolates, we sequenced all 22
samples in a 412-bp region upstream of the whiB7 gene start site
plus a portion of the whiB7 open reading frame. As a control set,
we also sequenced 30 randomly picked pan-susceptible isolates.
Of the 22 discordant isolates, 6 isolates from three patients showed
mutations in thewhiB7 5=UTR region. One sample had a cytosine
deletion at position 138 in the 5= UTR, two samples from one
patient contained an A-to-G mutation at position237, and the
remaining three samples from a single patient showed an A-to-C
mutation at position 273 (Table 3), considering the transcrip-
tion start site as1 (34). Three samples froma single patient failed
to generate any amplification from the 5=UTR after repeated PCR
attempts despite functioning positive PCR controls. This sug-
gested the presence of a large deletion in the 5=UTR sincewe could
easily amplify a 275-bp fragment from within the whiB7 ORF for
all the three samples. All the samples with whiB7 mutations were
resistant only to KAN, which is consistent with the presumed
whiB7 mechanism of action by upregulation of the eis gene (34).
The KANMICs for these isolates were also low at 5g/ml, a value
similar to that observed for eis promoter mutants. None of the 30
control samples that were susceptible to aminoglycosides had any
mutations in the 5= UTR of the whiB7 gene. Further studies are
necessary to confirm the relationship of these mutations and the
deletion in the 5= UTR of the whiB7 gene with aminoglycoside
resistance. However, the absence of suchmutations in the suscep-
tible strains implies that they might have some role to play in
aminoglycoside resistance, and future assays could target these
mutations to improve sensitivity for detecting low-level KAN re-
sistance.
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FIG 3 MIC values of rrs and eis mutant and wild-type strains. The average
AMK and KAN MIC values for the rrs and the eis mutants and the wild-type
strains are shown. Error bars represent themeans 1 standard deviation of the
MIC values. eis-P, eis gene promoter.
TABLE 3 Susceptibility of the clinical strains to AMK and KAN and
mutations in the 5= untranslated region of the whiB7 gene
Isolate
no.
Patient
no.
Susceptibility profile by
methoda
whiB7 5= UTR sequenceb
AMK
(LJ)
KAN
LJ MGIT
1 1 S S R NM
2 2 S S R NM
3 3 S S R NM
4 3 S S R NM
5 4 S R R NM
6 5 S R R 273, A¡C
7 5 S R ND 273, A¡C
8 5 S R R 273, A¡C
9 6 R R R NM
10 6 S S R NM
11 6 R R ND NM
12 7 S S R 138, C deletion
13 8 S S R NM
14 9 S S R Probable deletion in UTR
15 9 S S R Probable deletion in UTR
16 9 S S R Probable deletion in UTR
17 10 R R R NM
18 11 S S R NM
19 12 R R S NM
20 13 S R R 237, A¡G
21 13 S R R 237, A¡G
22 14 R R R NM
a LJ and MGIT susceptibility as determined by the LJ proportions and the MGIT
methods respectively. ND, not determined; R; resistant, S; susceptible.
b NM; no mutation. Shaded rows represent multiple samples from an individual
patient.
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DISCUSSION
Our multiplexed SMB PCR and melt assay accurately identified
mutations in the rrs gene and eis promoter associated with resis-
tance to AMK and/or KAN. The assay did not produce false resis-
tance calls when tested against NTM and Gram-positive and
Gram-negative bacteria. Most cases of heteroresistance, when
present, were also detected by the assay. Unlike the MTBDRsl
platform, our assay can be performed in a closed real-time PCR
system and can easily be adapted to high-throughput testing as all
assay steps are performed in 96-well plates. The SMB assay also
avoids potential problems associated with alternativemethods for
mutation detection. High-resolution melt curve analysis requires
the ability to detect subtle variations in melt curves (22). Other
post-PCR melt-based molecular assays must detect mutations by
decoding complex fluorescence contours (35). In contrast, the
SMB assay produces clear and easily distinguishable Tm peaks and
definitiveTm shifts to identify themutations of interest. Individual
Tm values can also be used to cluster samples that have the same
genotype.
We tested our assay on a panel of 603 clinical samples repre-
senting both new cases of TB as well as unresolved retreatment
cases and evaluated the relationship of the targeted mutations
with the susceptibility pattern of the clinical isolates.We observed
that 100% of the isolates with rrs A1401G mutations had a strong
correlation with high-level resistance to both AMK and KAN.
However, eis promoter mutations resulted in only moderate- to
low-level KAN resistance and no resistance to AMK, which is con-
sistent with previous studies (9, 33). Our study also showed that
the LJ absolute concentration method for susceptibility testing
does not adequately detect moderate- to low-level KAN resis-
tance. In fact, nearly two-thirds of the samples with eis promoter
mutations were detected as KAN susceptible in the LJ medium.
However, all but one sample with eis promoter mutations were
detected as KAN resistant by theMGITmethod. Two such isolates
contained an eis C(12)T mutation. These mutants were also
resistant to KAN when tested by MycoTB, which showed a KAN
MIC of 5 g/ml. Previous studies have suggested that clinical iso-
lates with C(12)T mutations do not correlate (33) or correlate
poorly (9, 17) with KAN resistance. These studies possibly missed
the relation between this mutation and low-level KAN resistance
due to the testing method used to establish phenotypic suscepti-
bility. These results suggest that the MGIT or MycoTB method
should be preferred for testing phenotypic resistance to KAN.
They also highlight the power of genotypic resistance tests, such as
ours, to detect mutations which cause low-level resistance and
may be missed by phenotypic tests alone (30, 31, 36).
Our study set included one sample that was a mixture of rrs
wild-type and rrsC1402Tmutants. This sample was susceptible to
both AMK and KAN in LJ medium. Isolates with C1402T muta-
tions have been reported to be susceptible to AMK but resistant to
KAN (32). In this particular case, repeated susceptibility tests us-
ing LJ medium showed susceptibility to KAN, presumably be-
cause of the heteroresistant nature of the sample. Here, the mo-
lecular assay served as a better predictor of potentially emerging
resistance than the phenotypic assay as the SMB assay clearly de-
tected the presence of both the wild-type and the mutant DNA
types.
The incidence of rrs codon 1484 mutations in clinical strains
with AMK or KAN resistance has been very low (12), making its
clinical significance debatable. A separate version of our assay
which targeted rrs codon 1484 did not detect anymutations in any
of the 603 isolates in our study or in an additional 259 isolates
from the New Jersey-New York area, which included 33 AMK-
and KAN-resistant isolates. The lack of any rrs codon 1484 muta-
tions in this enlarged study set was confirmed by Sanger sequenc-
ing (data not shown). In light of the very low prevalence of muta-
tions in rrs codon 1484, this codon is unlikely to provide much
value in predicting aminoglycoside resistance. Thus, we recom-
mend that molecular assays for aminoglycoside resistance target
only the 1401 and 1402 codons in the rrs gene.
We found 22 AMK- or KAN-resistant samples that had wild-
type sequences in the rrs gene and the eis promoter region. A
recent study has shown a possible association between mutations
in the 5=UTRof thewhiB7 gene andKAN resistance by identifying
a 5= UTR whiB7 mutation in a single clinical strain with unex-
plained KAN resistance (34). To our knowledge, our study is the
second to report that mutations in this region are associated with
KAN resistance. We also describe several novel 5= UTR whiB7
mutations, as well as a deletion, that appear to be associated with
KAN resistance. No suitable universal biomarkers have been iden-
tified which can account for KAN and AMK resistance in the re-
maining 15 to 20% of clinical strains with both wild-type rrs and
eis promoter region. Samples containingwild-type rrs gene and eis
promoter region DNA mixed with a trace amount of mutant tar-
gets from a KAN- or AMK-resistant subpopulation could also
account for the remaining discordances between phenotypic re-
sistance tests andour SMBassay.However, extensive investigation
of heteroresistance was beyond the scope of this study. Some re-
cent studies have suggested that PPE60 and Rv3168 genes might
be involved in unexplained KAN resistance (37, 38) although this
remains to be verified in clinical settings. Further studies are nec-
essary to confirm the relationship of these mutations to KAN re-
sistance.
In summary, we have developed a sensitive and specific assay
for detection of AMK and KAN resistance in M. tuberculosis and
validated it in clinical isolates with a high prevalence of MDR and
XDR TB. We show that rrs A1401G mutations encode high-level
cross-resistance to both AMK and KAN and that eis promoter
mutations encode moderate- to low-level KAN resistance, which
is consistent with previous functional genomics studies (33).
Comparing the performance of our assay with that of three differ-
ent phenotypic susceptibility testing methods in solid and liquid
media revealed that low- tomoderate-level KAN resistance caused
by eis promoter mutations is largely missed by the LJ-based sus-
ceptibility tests. These results strongly argue for the value of geno-
typic tests to detect aminoglycoside resistance, and the results
demonstrate the specific utility of our SMB-based assay.
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